Old Ⅲ Colorectal Cancer Survival After Radical Analysis And Evaluation Of Chemotherapy

Objective: To investigate the prognostic factors of elder colorectal cancer patients which stage isⅢand accepted postoperative adjuvant chemotherapy for, and the value of adjuvant chemotherapy; To investigate Efficacy and tolerance of chemotherapy between FOLFOX and oral Xeloda monotherapy inⅢcolorectal cancerMethods: Retrospective analysis the clinical follow-up data of 375 Liaoning Province Tumor Hospital's colorectal cancer patients who underwent radical resection and postoperative pathologic stage isⅢand accepted chemotherapy from 2003 to 2007.The data contain gender, disease location, tumor incidence area, degree of differentiation, morphological classification, preoperative CEA, depth of invasion and the number of lymph nodes . Evaluate the relevance between the factor and the rate of stageⅢ's disease-free survival after 3 years. we Investigate the differences in disease-free survival 3 years, adverse reactions and 3-year disease-free survival differences between FOLFOX and oral Xeloda programs.Results: Patients with 3-year disease-free survival rate was 59.47%. Univariate analysis showed that: the depth of invasion T1, T2 and T3, T4 of the 3-year disease-free survival, the difference was statistically significant (P = 0.008).The difference was statistically significant (P = 0.002) between The number of metastatic lymph nodes N〈7 and N>7. FOLFOX and oral Xeloda monotherapy 3-year disease-free rate was 60.87% and 58.12%, difference was not statistically significant. FOLFOX program with considerable adverse effects of Xeloda program, only hand-foot syndrome and peripheral nerve toxicity are different. Respectively, N<7, N>7, T1 + T2 and T3 + T4 levels were 3-year program of comparing the two disease-free survival, the difference was not statistically significant. Conclusion:1.T3, T4 is the poor prognosis factors of stageⅢcolorectal cancer in the elderly patients who accepted adjuvant chemotherapy after radical resection.2.N> 7 isⅢthe poor prognosis factors of stageⅢcolorectal cancer in the elderly patients who accepted adjuvant chemotherapy after radical resection.3.The 3-year disease-free survival rate of FOLFOX program was higher than Xeloda monotherapy program, but the difference was not statistically significant.4.The adverse effects between FOLFOX programs and Xeloda is roughly equal to the program, only hand-foot syndrome and peripheral nerve toxicity are different. There were no treatment-related deaths of two programs, two programs that are all safe.5. The was no difference in efficacy between FOLFOX program and Xeloda monotherapy program in the same level of T staging.6.The was no difference in efficacy between FOLFOX program and Xeloda monotherapy program in the same number of metastatic lymph node level.